ASX:OSL

OncoSil Medical Competitors

Add
Compare
Today's Range N/A
50-Day Range N/A
52-Week Range N/A
Volume2.17 million shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

OncoSil Medical (ASX:OSL) Vs. BUX, IME, BD1, CRL, CTE, and DVL

Should you be buying OSL stock or one of its competitors? Companies in the industry of "diagnostics & research" are considered alternatives and competitors to OncoSil Medical, including (BUX) (BUX), 12144 (IME), BARD1 Life Sciences (BD1), Charles River Laboratories International (CRL), Cryosite (CTE), and dorsaVi (DVL).

OncoSil Medical (ASX:OSL) and (BUX) (CNSX:BUX) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings and analyst recommendations.

Earnings and Valuation

This table compares OncoSil Medical and (BUX)'s gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSil Medical$2.22 million0.00$-5,651,400.83A($0.01)N/A
(BUX)N/AN/AN/AN/AN/A

(BUX) has lower revenue, but higher earnings than OncoSil Medical.

Profitability

This table compares OncoSil Medical and (BUX)'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncoSil MedicalN/AN/AN/A
(BUX)N/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and price targets for OncoSil Medical and (BUX), as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OncoSil Medical0000N/A
(BUX)0000N/A

Summary

OncoSil Medical beats (BUX) on 1 of the 1 factors compared between the two stocks.

OncoSil Medical (ASX:OSL) and 12144 (CNSX:IME) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, valuation, risk, profitability, analyst recommendations, earnings and institutional ownership.

Analyst Recommendations

This is a summary of recent recommendations for OncoSil Medical and 12144, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OncoSil Medical0000N/A
121440000N/A

Valuation & Earnings

This table compares OncoSil Medical and 12144's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSil Medical$2.22 million0.00C$-5,651,400.83A($0.01)N/A
12144N/AN/AN/AN/AN/A

12144 has lower revenue, but higher earnings than OncoSil Medical.

Profitability

This table compares OncoSil Medical and 12144's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncoSil MedicalN/AN/AN/A
12144N/AN/AN/A

Summary

OncoSil Medical beats 12144 on 1 of the 1 factors compared between the two stocks.

OncoSil Medical (ASX:OSL) and BARD1 Life Sciences (ASX:BD1) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

Earnings and Valuation

This table compares OncoSil Medical and BARD1 Life Sciences' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSil Medical$2.22 million0.00$-5,651,400.83A($0.01)N/A
BARD1 Life Sciences$612,251.000.00$-6,644,706.43A($0.08)N/A

OncoSil Medical has higher revenue and earnings than BARD1 Life Sciences.

Profitability

This table compares OncoSil Medical and BARD1 Life Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncoSil MedicalN/AN/AN/A
BARD1 Life SciencesN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for OncoSil Medical and BARD1 Life Sciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OncoSil Medical0000N/A
BARD1 Life Sciences0000N/A

Summary

OncoSil Medical beats BARD1 Life Sciences on 3 of the 3 factors compared between the two stocks.

OncoSil Medical (ASX:OSL) and Charles River Laboratories International (CNSX:CRL) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, valuation, dividends, earnings and profitability.

Profitability

This table compares OncoSil Medical and Charles River Laboratories International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncoSil MedicalN/AN/AN/A
Charles River Laboratories InternationalN/AN/AN/A

Analyst Ratings

This is a breakdown of recent ratings for OncoSil Medical and Charles River Laboratories International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OncoSil Medical0000N/A
Charles River Laboratories International0000N/A

Valuation & Earnings

This table compares OncoSil Medical and Charles River Laboratories International's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSil Medical$2.22 million0.00$-5,651,400.83A($0.01)N/A
Charles River Laboratories InternationalN/AN/AN/AN/AN/A

Charles River Laboratories International has lower revenue, but higher earnings than OncoSil Medical.

Summary

OncoSil Medical beats Charles River Laboratories International on 1 of the 1 factors compared between the two stocks.

OncoSil Medical (ASX:OSL) and Cryosite (ASX:CTE) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, dividends, risk, profitability and institutional ownership.

Profitability

This table compares OncoSil Medical and Cryosite's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OncoSil MedicalN/AN/AN/A
CryositeN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings for OncoSil Medical and Cryosite, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OncoSil Medical0000N/A
Cryosite0000N/A

Valuation & Earnings

This table compares OncoSil Medical and Cryosite's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OncoSil Medical$2.22 million0.00$-5,651,400.83A($0.01)N/A
Cryosite$9.71 million0.00$515,455.60A$0.01N/A

Cryosite has higher revenue and earnings than OncoSil Medical.

Summary

Cryosite beats OncoSil Medical on 3 of the 3 factors compared between the two stocks.

dorsaVi (ASX:DVL) and OncoSil Medical (ASX:OSL) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, risk, analyst recommendations, earnings, dividends, profitability and institutional ownership.

Profitability

This table compares dorsaVi and OncoSil Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
dorsaViN/AN/AN/A
OncoSil MedicalN/AN/AN/A

Earnings & Valuation

This table compares dorsaVi and OncoSil Medical's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
dorsaVi$1.65 million0.00$-3,158,396.93A($0.01)N/A
OncoSil Medical$2.22 million0.00$-5,651,400.83A($0.01)N/A

dorsaVi has higher earnings, but lower revenue than OncoSil Medical.

Analyst Recommendations

This is a breakdown of recent ratings for dorsaVi and OncoSil Medical, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
dorsaVi0000N/A
OncoSil Medical0000N/A

Summary

OncoSil Medical beats dorsaVi on 2 of the 3 factors compared between the two stocks.


OncoSil Medical Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
BUX
(BUX)
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
IME
12144
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
BD1
BARD1 Life Sciences
0.5N/AN/A$0.00$612,251.000.00High Trading Volume
Gap Up
CRL
Charles River Laboratories International
0.5N/AN/A$0.00N/A0.00Gap Up
CTE
Cryosite
0.6N/AN/A$0.00$9.71 million0.00High Trading Volume
Gap Up
DVL
dorsaVi
0.5N/AN/A$0.00$1.65 million0.00High Trading Volume
Gap Up
Epigenomics logo
EPGNY
Epigenomics
0.6$12.39flat$0.00N/A0.00Increase in Short Interest
ETAH
Eternity Healthcare
0.6$0.00flat$0.00N/A0.00
GSS
Genetic Signatures
0.0N/AN/A$0.00$29.13 million0.00High Trading Volume
GTG
Genetic Technologies
0.0N/AN/A$0.00$25,714.000.00High Trading Volume
IBX
Imagion Biosystems
0.6N/AN/A$0.00$2.70 million0.00High Trading Volume
Gap Up
IDX
Integral Diagnostics
0.8N/AN/A$0.00$314.82 million0.00High Trading Volume
Gap Up
LSH
Lifespot Health
0.5N/AN/A$0.00$22,127.000.00High Trading Volume
Gap Up
MEDD
Medical Imaging
0.4$0.01flat$0.00N/A0.00News Coverage
Parallax Health Sciences logo
PRLX
Parallax Health Sciences
0.5$0.01flat$0.00N/A0.00Gap Down
RHY
Rhythm Biosciences
0.0N/AN/A$0.00$1.21 million0.00High Trading Volume
Sartorius Aktiengesellschaft logo
SRT3
Sartorius Aktiengesellschaft
0.6$469.80flat$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
SENS
Senseonics
0.0N/AN/A$0.00N/A0.00High Trading Volume
Siemens Healthineers logo
SMMNY
Siemens Healthineers
0.5$28.05flat$0.00N/A0.00Decrease in Short Interest
News Coverage
SIL
Smiles Inclusive
0.4N/AN/A$0.00$36.48 million0.00High Trading Volume
Gap Up
VHT
Volpara Health Technologies
0.5N/AN/A$0.00$15.22 million0.00High Trading Volume
Gap Up
OBJ
Wellfully Limited (OBJ.AX)
0.0N/AN/A$0.00$1.48 million0.00High Trading Volume
WUXIF
WuXi AppTec
1.0$19.88flat$0.00N/A0.00
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.